股票简称：华海药业 股票代码：600521 公告编号：临 2023-087 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于"华海转债"预计触发转股价格向下修正的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 规定，"上市公司应当在预计触发转股价格修正条件的 5 个交易日前及时披露提示 性公告。"自 2023 年 7 月 27 日至 2023 年 8 月 9 日，公司股票在连续 30 个交易日 中已有 10 个交易日的收盘价低于当期转股价格的 80%，预计触发转股价格向下修 正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股价 格，并及时履行信息披露义务。 一、可转债上市发行概况 经中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发行可 转换公司债券的批复》（证监许可[2020]2261 号）核准，公司于 2020 年 11 月 2 日 公开发行了 1,84 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2023-049 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度经营成果及财 务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投 资者普遍关注的问题进行回答。 1 会议召开时间：2023 年 05 月 12 日（星期五） 下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议主题：沪市主板生物医药行业上市公司集体业绩说明会 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 05 日（星期五）至 05 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：600521 证券简称：华海药业 浙江华海药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-----------------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减变 \n动幅度 (%) | | 营业收入 | 2,058,913, ...

Financial Performance - The company's operating revenue for 2022 reached ¥8,265,744,793.28, representing a 24.42% increase compared to ¥6,643,573,143.13 in 2021[19]. - Net profit attributable to shareholders for 2022 was ¥1,167,758,749.48, a significant increase of 139.52% from ¥487,535,117.22 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥1,153,066,098.54, showing an impressive growth of 1,839.98% compared to ¥59,437,076.89 in 2021[19]. - The weighted average return on equity increased to 16.55% in 2022, up by 9.12 percentage points from 7.43% in 2021[20]. - The company reported a net cash flow from operating activities of ¥1,242,693,126.90, which is a 32.42% increase from ¥938,429,830.68 in 2021[19]. - The total assets at the end of 2022 were ¥18,151,737,482.18, reflecting a 17.35% increase from ¥15,468,124,894.16 at the end of 2021[19]. - Basic earnings per share for 2022 were ¥0.81, a 138.24% increase from ¥0.34 in 2021[20]. - The company achieved a record revenue of 8,265.74 million yuan in 2022, representing a year-on-year growth of 24.42%[27]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, reached 1,153.07 million yuan, a significant increase of 1,839.98% year-on-year[27]. Dividend Distribution - The company plans to distribute a cash dividend of 2.4 CNY per 10 shares, which represents 30.27% of the net profit attributable to ordinary shareholders for 2022[4]. - The total cash dividend amount for 2022 is 353,476,365.12 RMB, which represents 30.27% of the net profit attributable to ordinary shareholders in the consolidated financial statements[191]. - The total dividend amount, including share repurchase, is 403,496,311.07 RMB, accounting for 34.55% of the net profit attributable to ordinary shareholders[191]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm for the fiscal year 2022[3]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[6]. - The company has not violated decision-making procedures for providing guarantees[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its annual report[5]. - The company has not disclosed any significant changes in its registered address or office address during the reporting period[14]. - The company has confirmed that all board members attended the board meeting[3]. - The company has not faced any issues with more than half of the board members being unable to guarantee the authenticity of the annual report[7]. Market and Sales Performance - The company experienced a significant increase in sales volume due to the recovery of the market after the lifting of the FDA ban and the continuous expansion of its domestic formulation business[21]. - The company reported an increase in exchange gains due to the significant rise in the US dollar exchange rate, contributing to the overall profit increase[21]. - The domestic formulation sales maintained rapid growth, with an average annual compound growth rate exceeding 37.9% from 2020 to 2022[29]. - The company successfully won bids for three products in the seventh batch of national centralized procurement, enhancing market share and expanding the number of selected provinces[29]. - In the U.S. market, 31 out of 54 products had market shares ranking in the top three, with five products holding the number one position[28]. - Raw material sales grew by 18.67% year-on-year, with sales covering 106 countries and regions[30]. Research and Development - The company aims to enhance its research and development capabilities, with over 680 master's and doctoral talents currently on staff, covering various therapeutic areas[35]. - The company has established a comprehensive R&D capability covering biopharmaceuticals, chemical innovative drugs, cell therapy, generic drugs, and chemical raw materials, recognized as a national high-tech enterprise and a leader in the domestic pharmaceutical industry[42]. - The company has over 20 projects in its biopharmaceutical pipeline, with 11 projects currently in clinical trials, including a globally innovative dual-target anti-tumor drug project[44]. - The company has established eight major technology platforms, achieving breakthroughs in continuous flow and asymmetric synthesis technologies[32]. - The company invested a total of 120,190.72 million RMB in R&D during the reporting period, focusing on expanding its pipeline in biopharmaceuticals and small molecule new drugs[94]. Corporate Governance - The company adheres to corporate governance standards, ensuring independent operation of its board and committees, and has held 11 board meetings during the reporting period[155]. - The company has implemented a strict insider information registration management system, ensuring compliance with relevant laws and regulations to protect the rights of minority shareholders[157]. - The company’s governance structure complies with relevant laws and regulations, with no significant discrepancies noted in its governance practices[157]. - The company has established a long-term equity incentive mechanism to align employee interests with company development, promoting talent retention and governance improvement[157]. Strategic Initiatives - The company plans to continue expanding its domestic formulation business and capitalize on the recovery of the U.S. market following the FDA ban lift[62]. - The company aims to achieve a sales revenue of approximately 10 billion yuan in 2023, representing a year-on-year growth of about 20.98%[141]. - The company will focus on accelerating new product development and enhancing project management to expedite the market launch of new products[137]. - The company plans to deepen its global marketing system to enhance its competitive position in both international and domestic markets[138]. - The company is committed to improving its corporate governance structure and internal control mechanisms to enhance operational efficiency[146]. Risk Management - The company faces risks in new product development due to high technical difficulty, significant upfront investment, and lengthy approval cycles, which could adversely affect the recovery of initial investments if products fail to pass registration[147]. - The company is exposed to price volatility in raw materials, which could negatively affect financial performance; however, it is enhancing its core competitiveness by increasing the proportion of formulation business sales[151]. - Changes in industry policies could significantly impact market dynamics, operational models, and profitability if the company fails to adapt to regulatory adjustments[150]. Employee and Talent Management - The company has implemented a training program for employees, focusing on enhancing professional knowledge and leadership skills for management personnel[187]. - The company has a strategic approach to employee compensation, aligning with market levels and focusing on high-value positions[186]. - The company has a talent pool of over 100 high-level professionals with overseas backgrounds and 680 master's and doctoral talents, strengthening its R&D capabilities[54]. Environmental and Social Responsibility - The company invested approximately 303.76 million yuan in environmental protection during the reporting period[200]. - The management team emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2030[166].

Financial Performance - The company's operating revenue for the first half of 2022 reached CNY 3,823,472,246, representing a 25.97% increase compared to CNY 3,035,289,790 in the same period last year[16]. - Net profit attributable to shareholders of the listed company was CNY 567,996,952.57, up 10.15% from CNY 515,655,364.88 in the previous year[16]. - The net profit after deducting non-recurring gains and losses surged by 223.83%, amounting to CNY 583,462,815.48 compared to CNY 180,173,599.74 in the same period last year[16]. - The net cash flow from operating activities was CNY 490,746,363.49, an increase of 18.40% from CNY 414,468,577.16 in the previous year[16]. - The total assets of the company at the end of the reporting period were CNY 16,171,802,694.24, reflecting a 4.55% increase from CNY 15,468,124,894.16 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased by 8.32% to CNY 7,104,322,942.53 from CNY 6,558,842,119.10 at the end of the previous year[16]. - Basic earnings per share for the first half of 2022 were CNY 0.39, an increase of 11.43% compared to CNY 0.35 in the same period last year[17]. - The diluted earnings per share were CNY 0.39, up 8.33% from CNY 0.36 in the previous year[17]. - The weighted average return on net assets increased by 0.69 percentage points to 8.30% from 7.61% in the previous year[17]. - The company reported a significant increase in the weighted average return on net assets after deducting non-recurring gains and losses, rising to 8.53% from 2.66% in the previous year, an increase of 5.87 percentage points[17]. Research and Development - The company has over 20 ongoing research projects in the biopharmaceutical sector, with 11 projects currently in clinical trials, including a globally innovative dual-target anti-tumor drug[19]. - The company has established a comprehensive R&D system, including a global registration center and multiple research institutes in China and the US[34]. - The company is committed to accelerating the development of biopharmaceuticals and innovative drugs as part of its strategic transformation[19]. - The company has a pipeline of nearly 40 small-scale research and reserve projects in active pharmaceutical ingredients (APIs), focusing on difficult and niche products[38]. - The company has successfully obtained MPP authorization for Pfizer's COVID-19 drug, enhancing its market presence[41]. Market Position and Strategy - The company has established stable partnerships with over 800 pharmaceutical companies globally, with product sales covering nearly 100 countries and regions[19]. - The company is a major global supplier of cardiovascular raw materials, particularly for the classes of drugs known as "prils" and "sartans"[19]. - The company has diversified its sales strategies in response to national healthcare reforms, focusing on market penetration and efficiency improvements[24]. - The company utilizes multiple sales models for its overseas products, including self-sales, cooperative sales, and agency sales[23]. - The global pharmaceutical market size approached $1.4 trillion in 2020, with a projected growth rate of 4%-5% in the coming years[27]. - North America and Europe account for over 62% of the global pharmaceutical market, with sales shares of 40% and 22% respectively, while China's market share has reached 20%[29]. Financial Management - The company reported a foreign exchange loss of CNY 3,816,701.65, compared to a loss of CNY 2,121,475.62 in the previous year[137]. - The company incurred a credit impairment loss of CNY 5,095,385.43, compared to a loss of CNY 3,215,670.21 in the previous year[138]. - The company reported a net investment loss of CNY 17,603,236.63 for the first half of 2022, a significant decline from a gain of CNY 87,366,579.03 in the previous year[135]. - The company has a dynamic procurement plan that adjusts based on production schedules and inventory levels, ensuring timely supply[20]. - The company has implemented lean management practices to enhance production efficiency and improve supply chain coordination[47]. Environmental and Compliance - The company is focused on enhancing safety production and environmental management, implementing various measures to ensure sustainable development[50]. - The company reported actual emissions of COD at 3.39 tons and ammonia nitrogen at 0.17 tons in the first half of 2022, within the approved limits[77]. - The company has implemented a thermal oxidation system for organic waste gas treatment, ensuring compliance with emission standards[81]. - The company completed environmental impact assessments for two projects, including a 500-ton annual production project for Levetiracetam and a 6 billion tablet solid preparation project[86]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[89]. Shareholder and Capital Management - No profit distribution or capital reserve increase is planned for the half-year period, with no dividends or stock bonuses proposed[74]. - The company granted 3.94544 million shares under the 2021 restricted stock incentive plan, with a grant date of April 25, 2022, at a price of 9.55 CNY per share[75]. - A total of 12.2285 million shares were repurchased and canceled due to reasons such as the departure of some incentive objects and unmet performance assessments[75]. - The company has established a dedicated repurchase account and completed the cancellation of shares on June 28, 2022[76]. - The company reported a total of 805.45 million yuan in investments for the current year across various projects[58]. Risk Management - The company highlighted risks associated with new product development, including long approval cycles and high upfront investments, which could adversely affect future returns[65]. - The ongoing national drug procurement policy is expected to further decrease average profit margins in the pharmaceutical industry, impacting the company's financial performance[67]. - The fluctuation risk of raw material prices is increasing due to intense competition in the raw material market, which could negatively impact the company's operating performance[71]. - The company is closely monitoring exchange rate fluctuations, as significant changes could impact revenue and profit levels due to its international business operations[71]. - The company is accelerating its globalization strategy, but geopolitical tensions and trade conflicts may adversely affect its export business[71].

Financial Performance - The company's operating revenue for 2021 was approximately ¥6.64 billion, representing a 2.44% increase from ¥6.49 billion in 2020[19]. - The net profit attributable to shareholders for 2021 was approximately ¥487.54 million, a decrease of 47.57% compared to ¥929.82 million in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥59.44 million, down 92.72% from ¥816.26 million in 2020[19]. - The operating cash flow for the year was approximately 938.43 million RMB, a decrease of 39.67% compared to the previous year[21]. - Basic earnings per share fell by 46.88% to 0.34 RMB, with diluted earnings per share also at 0.34 RMB[22]. - The company's total assets increased by 19.07% from the end of 2020, reaching approximately 15.47 billion RMB[21]. - The company's revenue in the pharmaceutical industry grew by 20.1% year-on-year, reaching CNY 2,928.85 billion in 2021[34]. - The gross profit margin for the main business decreased by 3.65 percentage points to 60.17%[59]. - The company achieved a net profit of approximately 2.05 billion RMB in Q4 2021, but reported a net loss of approximately 102.08 million RMB in the same quarter[24]. Research and Development - Research and development investment reached a new high, focusing on biopharmaceuticals, new drugs, and generics[22]. - The company has over 1,500 R&D personnel, with annual R&D investment exceeding 10% of sales[40]. - R&D expenses increased by 66.57% to CNY 942.26 million, accounting for over 10% of sales[56]. - The company has established a comprehensive drug research and development platform, covering the entire lifecycle from antibody discovery to commercialization[51]. - The company initiated 11 biopharmaceutical research projects, with 5 clinical trial approvals received in 2021, enhancing long-term growth prospects[30]. - The company has a robust pipeline with multiple products in various clinical trial phases, including III phase trials for HOT-3010 targeting moderate to severe plaque psoriasis[92]. - The company is focused on expanding its product offerings in the oncology and autoimmune disease sectors, with several drugs in late-stage clinical trials[92]. Market and Sales - The sales revenue in key markets such as China, Southeast Asia, and the Middle East increased by over 50% year-on-year[28]. - Domestic formulation sales revenue increased by 38.08%, while foreign formulation sales decreased by 23.43%[58]. - The company has established a multi-channel marketing system in the U.S., covering 95% of major pharmaceutical purchasers[54]. - The company is actively expanding its domestic formulation market while maintaining a strong presence in international raw material markets[41]. - The company plans to establish high-end technology formulation R&D platforms over the next 3-5 years, including melt extrusion and soft capsule technologies[87]. Corporate Governance - The company maintains a robust governance structure, ensuring independence from its controlling shareholder and compliance with legal requirements[135]. - The company has implemented a complete insider information management system to prevent insider trading and protect minority shareholders' rights[138]. - The company respects and protects the legitimate rights and interests of stakeholders, including banks, creditors, employees, customers, suppliers, and consumers[137]. - The company has established a scientific performance evaluation system linking assessment results to employee salary levels and promotions[136]. - The company actively implements an equity incentive mechanism to align employee interests with company development, enhancing governance structure and operational sustainability[136]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, focusing on energy efficiency and the adoption of advanced technologies to replace outdated equipment[188]. - The company has established online monitoring systems at discharge points to ensure compliance with pollution discharge standards[181]. - The company is actively promoting green development and resource conservation as part of its corporate social responsibility initiatives[190]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[185]. - The company reported actual wastewater emissions of 6.08 tons of COD and 0.30 tons of ammonia nitrogen in 2021, which are within the approved limits[175]. Strategic Initiatives - The company plans to focus on innovation and structural adjustments in products and business to meet health demands and ensure sustainable growth[123]. - The company is committed to balancing internal growth with external expansion strategies to enhance its market position[123]. - The company aims to achieve a sales revenue target of 8.5 billion yuan for 2022, focusing on enhancing market share and expanding sales channels[126]. - The company is actively pursuing external collaborations and investments to support its growth strategy and enhance its innovation capabilities[126]. - The company is enhancing its internal management and operational efficiency to ensure sustainable and healthy development in a complex market environment[125]. Financial Management - The company has implemented a strict internal control management system in accordance with relevant laws and regulations, continuously improving and optimizing internal control systems to ensure compliance and safeguard shareholder interests[169]. - The internal control audit report for 2021 was issued by Tianjian Accounting Firm, confirming the effectiveness of the internal control with a standard unqualified opinion[171]. - The company has developed a financial derivatives trading management system to enhance its internal control framework[169]. - The company reported a total fair value of financial assets at the end of the period amounting to ¥594,559,029.78, with trading financial assets contributing ¥530,715,377.13[110]. - The company’s cash and cash equivalents decreased by 15.17% to 1,876.30 million yuan, representing 12.13% of total assets[71].